

A dark blue horizontal banner with the text 'PRESS RELEASE' in white, uppercase letters. To the left of the banner is a solid orange circle.

PRESS RELEASE

Sosei Heptares notes PeptiDream announced achievement of milestone in PAR2 peptide antagonist collaboration

Tokyo, Japan and Cambridge, UK, 12 May 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) notes that its partner PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”; TOKYO: 4587) announced today the achievement of an important milestone in its ongoing collaboration with the Company to discover, develop and commercialize novel peptide therapeutics targeting PAR2, a G protein-coupled receptor (GPCR) with an important role in inflammatory diseases and pain. The full announcement from PeptiDream is available [here](#).

As per the terms of the agreement, Sosei and PeptiDream jointly conduct and share the costs of the discovery and development program and will co-own any resulting products.

Miles Congreve, Sosei Heptares Chief Scientific Officer, said: “The development of peptide therapeutics for delivery via an oral route can be challenging, given the gut is extremely efficient at breaking such molecules down. For PAR2, by designing peptide leads that are stable in the gut environment, Sosei Heptares and PeptiDream have overcome a potential challenge and limiting factor for therapeutic development of a peptide for this target.”

-ENDS-

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit <https://www.soseiheptares.com/>

LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)

A dark blue horizontal banner with a white circle on the left side, containing the text 'PRESS RELEASE' in white capital letters.

PRESS RELEASE

Enquiries:

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, SVP Investor Relations and Corporate Strategy

+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Citigate Dewe Rogerson (for Sosei Heptares)

Yas Fukuda – Japanese Media

+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com

Mark Swallow, David Dible – International Media

+44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.